M&A Deal Summary |
|
|---|---|
| Date | 2009-10-14 |
| Target | Eli Lilly & Co - Tippecanoe Laboratories |
| Sector | Life Science |
| Buyer(s) | Evonik Industries |
| Sellers(s) | Lilly |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1873 |
| Sector | Diversified |
| Employees | 31,273 |
| Revenue | 15.2B EUR (2024) |
Evonik Industries is an industrial corporation with worldwide operations grouped in three business areas Chemicals, Energy and Real Estate which are positioned at the forefront of their market segments. It is a global leader in specialty chemicals (former Degussa), an expert in power generation from hard coal and renewable energies (former STEAG) and one of Germany's largest privately owned residential real estate companies. Evonik Industries was founded in 1873 and is based in Essen, Germany.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 12 |
| Sector: Life Science M&A | 1 of 3 |
| Type: Divestiture M&A Deals | 1 of 3 |
| State: Indiana M&A | 1 of 1 |
| Country: United States M&A | 2 of 6 |
| Year: 2009 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-05-16 |
United Initiators
Pullach, Germany United Initiators is a global manufacturer of peroxides, persulfates and other specialty initiators. United Initiators’ products comprise organic peroxides, persulfates, hydrogen peroxide and speciality chemicals, which have a wide range of applications including the production of acrylics and latex polymers, paint, plastics, bleaching agents, denture cleaners, teeth whiteners and disinfectants. United Initiators was founded in 1911 and is based in Pullach, Germany. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2010-03-02 |
Evonik MET
London, United Kingdom Evonik MET Ltd. is a chemical separations specialist supplying the pharmaceutical and fine chemicals industries. MET has an international client base spanning the USA, Europe and the Far East. |
Buy | €5M |
| Category | Company |
|---|---|
| Founded | 1876 |
| Sector | Life Science |
| Employees | 43,000 |
| Revenue | 45.0B USD (2024) |
Lilly discovers, develops, manufactures, and markets products in two business segments—human pharmaceutical products and animal health products. The mission of its human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Most of the products Lilly sells were discovered or developed by its own scientists, and the Company's success depends to a great extent on its ability to continue to discover, develop, and bring to market innovative new medicines. The company's animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. The company manufactures and distributes its products through facilities in the US, Puerto Rico, and 11 other countries. Lilly was founded in 1876 and is based in Indianapolis, Indiana.
| DEAL STATS | # |
|---|---|
| Overall | 7 of 10 |
| Sector: Life Science M&A | 2 of 3 |
| Type: Divestiture M&A Deals | 6 of 9 |
| State: Indiana M&A | 3 of 6 |
| Country: United States M&A | 7 of 10 |
| Year: 2009 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-10-06 |
ImClone Systems
Bridgewater, New Jersey, United States ImClone Systems is a fully integrated biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey. |
Buy | $6.5B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2010-07-02 |
Alnara Pharmaceuticals
Cambridge, Massachusetts, United States Alnara Pharmaceuticals, Inc., a privately held biotechnology company developing protein therapeutics for the treatment of metabolic diseases. Alnara's lead product in development is liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT). Liprotamase is under review by the U.S. Food and Drug Administration for the treatment of exocrine pancreatic insufficiency (EPI). Causes of EPI include cystic fibrosis, chronic pancreatitis, pancreatectomy and other conditions. |
Buy | $180M |
